Fortfahren mit
Größe auswählen
| Größe/SKU | Verfügbarkeit | Preis |
|---|---|---|
25 mg | Warenkorb auf Verfügbarkeit prüfen | € 502,00 |
Über diesen Artikel
grade
pharmaceutical primary standard
agency
USP
API family
rosiglitazone
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
pharmaceutical
format
neat
storage temp.
2-8°C
SMILES string
S1\C(=C/c2ccc(cc2)OCCN(C)c3ncccc3)\C(=O)NC1=O
InChI
1S/C18H17N3O3S/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15/h2-9,12H,10-11H2,1H3,(H,20,22,23)/b15-12-
InChI key
HCDYSWMAMRPMST-QINSGFPZSA-N
General description
Application
Analysis Note
Other Notes
1 of 1
Dieser Artikel | |||
|---|---|---|---|
| description United States Pharmacopeia (USP) Reference Standard | description pharmaceutical analytical impurity (PAI) | description United States Pharmacopeia (USP) Reference Standard | description Pharmaceutical Secondary Standard; Certified Reference Material |
| grade pharmaceutical primary standard | grade pharmaceutical analytical impurity (PAI) | grade pharmaceutical primary standard | grade pharmaceutical secondary standard, certified reference material |
| manufacturer/tradename USP | manufacturer/tradename USP | manufacturer/tradename USP | manufacturer/tradename - |
| application(s) pharmaceutical (small molecule) | application(s) pharmaceutical small molecule | application(s) pharmaceutical | application(s) pharmaceutical |
| format neat | format neat | format neat | format - |
| agency USP | agency USP | agency USP | agency traceable to USP 1605817 |
| API family rosiglitazone | API family - | API family rosiglitazone | API family rosiglitazone |
Signalwort
Warning
Gefahrencodes
Sicherheitshinweise
Hazard Classifications
Acute Tox. 4 Oral
Lagerklasse
11 - Combustible Solids
Flammpunkt (°F)
Not applicable
Flammpunkt (°C)
Not applicable
Hier finden Sie alle aktuellen Versionen:
Besitzen Sie dieses Produkt bereits?
In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.


